Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Share-based Compensation for 2 consecutive years, with -$86000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 102.16% to -$86000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, down 50.49% year-over-year, with the annual reading at $8.1 million for FY2025, 50.49% down from the prior year.
  • Share-based Compensation hit -$86000.0 in Q4 2025 for Silence Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2024 to a low of -$86000.0 in Q4 2025.